ClinicalTrials.gg
CompletedNCT05653037Updated Sep 1, 2026

A Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD4059 in Healthy Subjects

A Phase 1 interventional study of RBD4059 and Placebo in Healthy Volunteers, sponsored by Suzhou Ribo Life Science Co. Ltd.. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Suzhou Ribo Life Science Co. Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a Randomized, Single-blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of Subcutaneously Administered RBD4059 in Healthy Subjects. The study will be performed in single ascending dose (SAD) phase in healthy subjects. The decision to escalate to subsequent dose levels will be made by the SRC based on the review of all available safety information and PK/PD data in each cohort.

RBD4059, a GalNAc conjugated siRNA, is an FXI-targeted new molecular entity independently developed by Ribo using its proprietary siRNA delivery system - RIBO-GalSTARTM.

Read the detailed description

RBD4059, a GalNAc conjugated siRNA, is an FXI-targeted new molecular entity independently developed by Ribo using its proprietary siRNA delivery system - RIBO-GalSTARTM. As a GalNAc-based liver targeting delivery system, RIBO-GalSTARTM incorporates a unique technology for the delivery of oligonucleotide therapeutics for various targets and indications associated with the liver, thus enabling highly specific and highly durable enrichment of the siRNA in hepatocytes, the primary source of FXI. RBD4059 is, therefore, proposed to be a novel effective and durable antithrombotic treatment, with low bleeding risk via inhibition of FXI activity and prolongation of APTT.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Suzhou Ribo Life Science Co. Ltd. is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female (non- only), aged 18 to 65 years, inclusive.
  • (BMI) between 18 and 32 kg/m2, inclusive.
  • , Prothrombin time(PT), INR, thrombin time (TT),FXI activity must be within the normal reference range (as per the local laboratory reference range) at screening .
  • Adequate complete blood counts (CBCs) and are within the normal reference range (If CBCs are outside the reference range, unless not determined by the Investigator ).
  • Healthy as determined by pre-study medical history, vital signs, physical examination, clinical laboratory assessments, and 12-lead (ECG).
  • Subjects who are willing to cooperate with the study staff, comply with the study requirements, complete the study according to the relevant procedures specified in the protocol, and correctly understand and sign the form in writing.

Exclusion criteria

Exclusion Criteria:

  • Any uncontrolled or serious disease that may interfere with participation in the clinical study and/or put the subject at significant risk (according to Investigator's judgment) if he/she participates in the clinical study.
  • History or presence of cardiovascular disease (including peripheral artery and cerebrovascular disease).
  • Systolic blood pressure (SBP) is less than 90 or greater than 140 mmHg and/or diastolic blood pressure (DBP) is less than 40 or greater than 90 mmHg after 10 minutes of supine rest, unless determined by the Investigator to be not .
  • Diagnosis of diabetes mellitus, history of gestational diabetes that is fully resolved is not permitted.
  • Any conditions which, in the opinion of the Investigator, would make the subject unsuitable for enrollment or could interfere with the subject's participation in or completion of the study.

Note: additional inclusion/exclusion criteria may apply, per protocol.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    RBD4059 SAD experimental group

    Subjects in SAD experimental groups will receive a single subcutaneous injection of RBD4059 on Day 1.

    Drug: RBD4059

  • Placebo comparator
    Placebo SAD group

    Subjects in SAD placebo groups will receive a single subcutaneous injection of placebo on Day 1.

    Drug: Placebo

Interventions

  • Subcutaneously Administered RBD4059 in Healthy Subjects.

  • DrugPlacebo

    Subcutaneously Administered Placebo in Healthys Subject.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v5.0

    Time frame: SAD: Up to Day 169 ;

Secondary outcomes

  1. To characterize the pharmacokinetics (PK) of RBD4059 in healthy subjects:Cmax

    Time frame: Up to 48 hours post-dose

  2. To characterize the pharmacokinetics (PK) of RBD4059 in healthy subjects:Tmax

    Time frame: Up to 48 hours post-dose

  3. To characterize the pharmacokinetics (PK) of RBD4059 in healthy subjects:AUC0-t

    Time frame: Up to 48 hours post-dose

  4. To characterize the pharmacokinetics (PK) of RBD4059 in healthy subjects:AUC0-inf

    Time frame: Up to 48 hours post-dose

  5. To characterize the pharmacokinetics (PK) of RBD4059 in healthy subjects:t1/2

    Time frame: Up to 48 hours post-dose

  6. To characterize the pharmacokinetics (PK) of RBD4059 in healthy subjects:MRT

    Time frame: Up to 48 hours post-dose

  7. To characterize the pharmacokinetics (PK) of RBD4059 in healthy subjects:λz

    Time frame: Up to 48 hours post-dose

  8. To characterize the pharmacokinetics (PK) of RBD4059 in healthy subjects:CL/F

    Time frame: Up to 48 hours post-dose

  9. To characterize the pharmacokinetics (PK) of RBD4059 in healthy subjects:Vz

    Time frame: Up to 48 hours post-dose

  10. To evaluate the pharmacodynamics (PD) effect of RBD4059 on levels of Coagulation factor XI (FXI) antigen in healthy subjects.

    Time frame: SAD: Up to Day 169 ;

  11. To evaluate the pharmacodynamics (PD) effect of RBD4059 on levels of FXI activity in healthy subjects.

    Time frame: SAD: Up to Day 169 ;

  12. To evaluate the pharmacodynamics (PD) effect of RBD4059 on levels of Activated partial thromboplastin time (APTT) in healthy subjects.

    Time frame: SAD: Up to Day 169 ;

07

Study locations

1 site
  • Q-Pharm Pty Limited
    Brisbane, Australia
08

References and documents

Publications

  • Gabrielsen A, Ueckert S, Nilsson C, Egnell AC, Fu J, Wikstrom J, Svedlund S, Friend R, Zhang H, Liang Z, Gao S, Gan LM. RNA interference therapy targeting coagulation factor XI: a first-in-human trial of RBD4059 (vortosiran). Blood Adv. 2026 Apr 14;10(7):2541-2548. doi: 10.1182/bloodadvances.2025018348. PubMed 41512172 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Oct 2024, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2022
First posted
Dec 16, 2022
StartActual
Mar 21, 2023
Primary completionActual
Oct 1, 2024
CompletionActual
Nov 10, 2025
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05653037
Responsible party
Sponsor
First posted
Dec 16, 2022
Start date
Mar 21, 2023
Primary completion
Oct 1, 2024
Completion
Nov 10, 2025
Last update
Sep 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: RBD4059

Start the discussion